INTRODUCTION
In 1929, Taylor [1] described "semi-malignant" serous tumors of the ovary which, although histologically aggressive with implants throughout the peritoneal cavity, were clinically benign. In fact, several patients had long-term survival even though they had incomplete surgical excision of the tumor from the peritoneal cavity. It was much later, in 1961, that the International Federation of Gynecology and Obstetrics (FIGO) recognized these proliferative tumors and in 1971 divided the common epithelial ovarian cancers into three subgroups: benign, borderline, and malignant [2] . The World Health Organization (WHO) accepted this histologic classification of ovarian tumors into these categories in 1973 [3] .
Later, Hart and Norris [4] gave guidelines for the concept of borderline ovarian tumors of mucinous subtype. These concepts were further clarified and later expanded beyond the serous and mucinous tumors to include the other histologic types, including endometrioid carcinoma, Brenner tumors, and clear cell carcinoma [5-1 1] . In general, borderline tumors are characterized as neoplasms exhibiting cellular proliferative changes greater than the benign form of the same type of tumor, but not showing destructive invasion of the ovarian stroma.
More specifically, the serous neoplasms are generally characterized by the presence of papillary serous excrescences with complex branching and epithelial tufting. The papillary stalks can be lined by cells two or three layers thick that show mild to moderate degrees of atypia. Psammoma bodies are frequently found. Mitosis, necrosis, and significant pleomorphism are absent.
In the mucinous tumors, there may be a variety of cystic and papillary structures lined by tall columnar mucinous epithelium two or three cell layers thick. The cells may show marked atypia with large hyperchromatic nuclei. Mitoses and invasion of stroma are absent. There should be no desmoplastic response in the ovarian stroma secondary to the glandular outpouching formation. Furthermore, it is important that the pathologic finding of glandular inclusion cysts lined by tubal or serous epithelium in the omentum, peritoneum, or nodes be described as endosalpingiosis and not be 351 considered as evidence of disease. This distinction is important not only at the initial staging procedure but also at evaluation for persistent disease, such as at second-look surgery.
The separation of ovarian neoplasms into malignant and borderline forms is crucial, because the pathobiology and prognosis for these two entities are markedly different, and particularly since borderline ovarian tumors account for between 9.2 percent and 16.3 percent of all ovarian neoplasms [ 1 2-14] .
This review of the English-language literature from 1979 to 1989 will concentrate on the justification for adjuvant treatment after surgery in borderline ovarian tumors. In early-stage cancer (stage I), there are several studies which suggested that no adjuvant therapy is needed and, in fact, conservation of ovarian tissue is acceptable. In the more advanced stages, the question appears still to be open.
Statistical analysis of the differences in percentages was done, using either the chi-square test or Fisher's exact test, where appropriate, and using .05 as the level of significance.
AGE, GRAVITY, AND PREGNANCY In general, patients with borderline ovarian tumors are younger than those with invasive ovarian carcinoma; in the most recent FIGO report of 1988, over 25 percent of the patients with borderline ovarian tumors were under the age of 40, while, for invasive ovarian tumors, less than 10 percent are under this age [15] . In the Genadry et al. [ 16] review of 154 patients, the range of ages was from 6 to 102, with a peak during the reproductive years. In Chambers et al. [17] , the mean age was 44.1 years and the median was 40.4 years, with a range of 15 to 85 years, and 47 percent were younger than age 40. Nulliparity, which may reflect the younger age of the patients, has been noted in a number of studies; e.g., Chambers et al. [17] reported that 29 percent were nulliparous, and Bostwick et al. [18] , 43.1 percent. Genadry et al. [16] noted that 38 percent of their population with borderline ovarian cancer was nulliparous; however, only 25 percent of the patients over age of 20 were nulliparous. Finally, several reports noted an association with pregnancy [16] [17] [18] [19] . In Chambers et al. [17] , four patients were pregnant at the time of presentation, of whom two were recognized at Cesarean section; however, these four patients constituted only 9 percent of the patients under the age of 40. Genadry et al. [16] reported on 14 patients who were pregnant at the time of initial diagnosis; they represented 9 percent of the total population and 15.9 percent of the patients younger than age 40. Several patients have also been found during infertility evaluation [17, 20] . It would appear that these associations are not causal relationships but reflect the younger population in which this type of neoplasm occurs.
Few studies comment on the racial background of the patients with borderline ovarian tumors, but Genadry et al. [16] noted no racial difference from the general population of their study.
SIGNS AND SYMPTOMS Abdominal and/or pelvic pain has been recorded as a presenting symptom in 20 percent to 58 percent of the patients; following this, the most common complaint was increasing abdominal girth in 40-43 percent of the patients [13, 14, 18, [21] [22] [23] . Other symptoms included increased urinary frequency, dyspareunia, abnormal vaginal Table 2 shows that there were 876 tumors characterized. The overwhelming histology was serous (60.3 percent), followed by mucinous (33.7 percent). Endometrioid, Brenner, and clear cell neoplasms accounted for only 30 histologies, while 2.6 percent were mixed histologic subtypes. In general, mucinous neoplasms occurred at a lower stage; e.g., in Chambers et al. [17] , only 6.0 percent of these were stage III compared with 16.4 percent of the serous neoplasms were stage III. Others have reported no mucinous tumors beyond stage I [18, 32] .
Bell and colleagues [33] in a review of 56 patients with serous borderline tumors have identified four significant histologic characteristics of the tumor. In their review, all patients had peritoneal implants and an evaluation was done of the invasiveness of the metastatic lesion, the cytologic atypia, the mitotic index, and the residual disease after primary surgery. The overall survival at five and ten years was 96 percent and 77 percent among these patients; however, among those with no high-risk factors there were no deaths due to tumor. This result compares with the patients with one or more of these characteristics where the ten-year survival rate was only 56 percent. Furthermore, the most significant factor was the "invasive" implants. Among the 50 patients without this type of peritoneal spread, only three died of the disease; on the other hand, four of the six patients with invasive implants died of disease. This report raises the question as to whether or not in a high-risk group with "invasive" implants adjuvant treatments should be tried. In a report by Michael and Roth [34] of 13 patients, there was no difference in survival between the group with invasive implants and those without these. McCaughey et al. [35] in another small series found that five patients with invasive implants had progressive disease, compared with only two patients of 13 without invasive implants. These discrepancies may reflect a difference in the definition of the invasive peritoneal implants. The question of appropriate treatment in a high-risk group, however, still has not been answered.
TUMOR MARKER, CA-125
The role of the serum tumor marker, CA-125, in borderline ovarian tumors has not been defined as it has been in the management and detection of invasive ovarian carcinoma. In several reports of small series of three or four patients, the serum CA-125 levels have been noted to be elevated in patients with borderline ovarian tumors [36] [37] [38] . The actual values were usually lower than those for invasive neoplasms. In Chambers et al., there were only four of 18 patients with borderline tumors in whom the serum CA-125 level was elevated. Interestingly, in one patient treated originally with an ovarian cystectomy, a recurrence was found concomitantly with a rise in the serum CA-125 level to 96 U/ml. This finding suggested a possible role in the follow-up of patients with borderline ovarian tumors. Recently, Rice et al. [39] reported in a review of borderline ovarian tumors that six of eight patients with elevated serum CA-125 levels had greater than stage I disease, while all five patients with stage I disease who had determination of CA-125 had normal levels. The reported number of patients with serum determinations of CA-125 is too small to generalize, if elevated levels correlate with aggressive or recurrent borderline ovarian tumors.
STAGE I AND STAGE II TREATMENT
The mainstay of treatment for early ovarian carcinoma is surgery. There is only one prospective randomized study in the literature on the treatment of borderine ovarian tumors. This study by Creasman et al. [29] addresses the problem of adjuvant therapy in stage I borderline ovarian tumors. In this 1982 paper, 55 patients with stages IA orIB disease were randomized after a minimum of a total abdominal hysterectomy and bilateral salpingo-oophorectomy to either no further treatment (25 patients), pelvic irradiation of 5,000 rads over five to six weeks (13 patients), or melphalan 0.2 mg/kg for five days every four weeks for 18 months(17 patients). There was only one patient in a three-year follow-up who had a recurrence, and she died of disease. This patient presented with a large tumor, measuring 34 cm, which ruptured intraoperatively and was treated with radiation. Nine months after original surgery the patient was found to have carcinomatosis and subsequently died. She may have been understaged, in retrospect. This report concluded that surgery alone was as efficacious as adjuvant treatment in these patients. Other reports of stage I disease address the conservative treatment of these patients. Julian and Woodruff [40] showed that, in 25 patients with stage IA disease and five-year follow-up, there was 100 percent survival with either unilateral oophorectomy or hysterectomy and bilateral oophorectomy. Tazelaar et al. [28] , in a series of 61 patients with stage IA disease, compared 41 patients who were treated with a total abdominal hysterectomy and bilateral salpingo-oophorectomy to 20 patients who were treated with more limited surgery, including four with cystectomy and 16 with unilateral adnexectomy. In the conservatively treated group, 15 percent had recurrence compared to 5 percent in the other group; however, on further analyses, all 61 patients remained alive with no clinical evidence of disease after the surgery for recurrent disease, at a follow-up of 36 to 244 months. The conservatively treated group tended to develop recurrent disease earlier than those in the other group; however, the difference in relapse-free survival between the two groups was not statistically significant. Since there were no recurrences of the mucinous tumors, there was a 23 percent recurrence rate in the serous neoplasms treated conservatively compared with a 7 percent rate in the other group. In Chambers et al. [17] , 27.4 percent (20 patients) of the patients with stage I disease were treated with conservative operations; within this group, three patients subsequently developed recurrent disease, two after an ovarian cystectomy alone. These two recurrences came earlier than the other recur-rences in stage I disease, at 12 and 15 months after initial surgery, compared with recurrences at 23, 34, and 47 months. Furthermore, one of these patients had an invasive ovarian carcinoma at recurrence. It would appear that conservation of ovarian tissue is justified with these low recurrence rates and general overall excellent survival.
The next question is: how conservative can the operation be? Lim-Tan et al. [20] reviewed a series of 33 patients with stage I disease treated with ovarian cystectomy. Four patients (12 percent) developed persistent or recurrent disease in the ipsilateral or contralateral ovary; ipsilateral persistence or recurrence occurred in 8 percent. If the resection margin of the specimen was positive for a neoplasm or there was removal of more than one cyst, then persistence or recurrence almost always occurred. All the patients were alive without evidence of disease in follow-up at 3-18 years. In this study, however, 60 percent of the patients underwent additional surgery (and some with total abdominal hysterectomy and bilateral salpingo-oophorectomy) shortly after the initial ovarian cystectomy. This study concluded that ovarian cystectomy was justified to preserve fertility in young women provided that the full extent of the disease was known. Although these authors do not favor a biopsy of a normal-appearing contralateral ovary, because of the risk of adhesion formation and increased mechanical infertility of approximately 14 percent [41] , this reviewer thinks that the biopsy is necessary in order to stage the disease accurately, since up to 5-10 percent of normal-appearing ovaries will have microscopic disease [42] . Eight of the 16 patients with stage I disease who were treated conservatively by Lim-Tan et al. [20] subsequently had a normal pregnancy.
In general, although there is only one prospective randomized study on the treatment of stage I disease, it would appear that for those patients who have surgically treated stage I disease, a unilateral adnexectomy is sufficient, with careful follow-up. Of the group of patients in Table 3 who had no adjuvant therapy after surgery, at least 11 of the 18 recurrences were in a preserved ovary. From Table 3 it can be seen that of the 450 patients who did receive adjuvant therapy, 20 patients (4.4 percent) either died of disease or had recurrent or persistent disease. If this result is compared with the 134 patients who received various adjuvant treatments, there were 13 patients (9.7 percent) who had similar fates. Although, using chi-square analysis in these outcomes, the difference was significant (chi-square = 4.41 1; p = 0.037), it must be remembered that the criteria for additional therapy were not stated in the various papers and may have included inadequate staging. Thus, the increased poor outcome in the treated group may reflect other factors than the treatments. Table 4 summarizes the data on 75 patients with stage II borderline tumors treated with various post-operative modalities; 28 percent received no adjuvant treatment and 36 percent received chemotherapy. Using Fisher's exact test to analyze the outcome of recurrence, persistence, and death between those receiving and those not receiving adjuvant treatments, there was no difference in outcome (p = 0.244). Again, none of these results is from a prospective randomized study. In this stage of the disease, the surgery should be a total abdominal hysterectomy and bilateral salpingo-oophorectomy, along with appropriate sampling of the peritoneal cavity.
In these early stages of disease, the question of the spillage of tumor from a ruptured neoplasm is noted by several authors. Hopkins et al. [21] reported on seven such patients with early disease who did not have recurrence in the peritoneum; six of these patients received no adjuvant therapy. Tasker and Langley [19] had operative spillage in 12 patients, and this event did not adversely affect the outcome. In the review of the literature by Yoonessi et al. [23] , they note reports on 15 patients with ovarian tumor rupture, none of whom had recurrence or died of disease. On the other hand, they noted that ascites or positive peritoneal cytology was a bad prognostic factor with four of 14 patients dying from the disease. STAGE III AND STAGE IV TREATMENT The patients who raise the most controversy about additional treatment are those who have intra-abdominal, retroperitoneal, or distant spread of the disease. Although this condition represented approximately 17.2 percent of the patients with borderline ovarian tumors, few details of the treatment with outcome were available. Of the papers cited, there were only 139 patients with stage III borderline ovarian tumors discussed. In Table 5 , it can be seen that 51.7 percent of the patients were treated with adjuvant chemotherapy (both alkylating agents and/or various combination chemotherapy regimens, sometimes including cis-platinum), 23.0 percent with radiation (external beam irradiation or intraperitoneal radioactive colloids), and 15.1 percent with a combination of radiation and chemotherapy. Only 14 (10.0 percent) patients received no treatment in addition to the surgery.
An important issue, however, in trying to decide what effect additional treatment had, is knowing the details of the initial surgery; unfortunately, these were not often discussed. In some cases, the patients had only an exploratory laparotomy and biopsy of the tumor, while in other series aggressively debulking surgery was performed. Tasker and Langley [ 19] , in 20 patients with extraovarian spread of the disease (five of whom died of disease), noted no influence of residual disease on the outcome for patients treated with various modalities. On the other hand, Bostwick et al. [18] noted that the two patients with stage III disease who died had incomplete excision of the neoplasm at initial surgery. Kliman et al. [25] reported on five patients with residual tumor after surgery who did not receive post-operative treatment; four were alive and well from 5.5 to 19 years after diagnosis. Table 5 shows that the percentage of recurrences and deaths was highest in the groups of patients who had no additional therapy (50 percent) or who were treated with radiation plus chemotherapy (61.9 percent). Further analyses, again using chi-square to compare the outcome of the group of patients not receiving adjuvant therapy to the patients receiving adjuvant therapy (chi-square = 0.6756; p = 0.794), showed the difference was not significant. Moreover, deaths from complications of treatment must be stressed in a disease which in general has an overall good survival. There were reports of patients developing leukemia and even dying from leukemia secondary to prolonged use of alkylating agents, a death due to cardiomyopathy after receiving doxorubicin, and a death secondary to septicemia associated with neutropenia due to treatment [14, 17, 19, 21, 24, 27] .
The number of patients treated for stage IV disease was too few to analyze and is summarized in Table 6 .
SECOND-LOOK SURGERY In general, in the more recent studies, if adjuvant treatment was employed, it was usually chemotherapy, although Hopkins et al. [21] reported greater use of radiation with or without chemotherapy. Most papers do not specify the details of drugs or doses Ten patients subsequently underwent second-look surgery, and all patients were found to be grossly and histologically positive for recurrent disease. Of this group, five patients subsequently continued to take melphalan for 12 additional courses, and, at third-look surgery, all patients were histologically positive for disease. No other study consistently treated all the patients. Nation and Krepart [13] reported on ten patients (five with stage I, one with stage II, and four with stage III), treated with either melphalan or cis-platinum combination chemotherapy, who had second-look surgery. They observed that none of the patients with microscopic disease at the end of the initial surgery had a negative second-look On the other hand, in the report by Chambers et al. [17] , ten-patients (four with stage I, two with stage II, and four with stage III) underwent second-look surgery, and two had evidence of disease; one had been treated with melphalan and the other with cis-platinum. Of the four patients with microscopic disease at the end of the primary surgery, only one had a positive second-look surgery.
Kliman et al. [25] reported on five patients with residual but non-measurable stage III disease, treated post-operatively with combination chemotherapy; all had positive second-look surgery. They reported an overall response rate of 9.1 percent to chemotherapy, and it was a partial response. It would appear from several reports, although not all, that even microscopic disease at the end of the initial surgery predicts a positive second-look surgery.
In the report of Fort et al. [24] , no patient with negative second-look surgery had a recurrence, but the follow-up was short; furthermore, of the 24 staged patients who underwent second-look surgery, three were positive, and two of these patients died of disease.
Yoonessi et al. [23] reported negative second-look surgery after a combination of doxorubicin, cis-platinum, cyclophosphamide, 5-fluorouracil, and methotrexate, although details of histology and the number of patients treated were not given.
Hence, the only detailed report on second-look surgery, by O'Quinn and Hannigan [27] , clearly showed that melphalan did not eliminate borderline ovarian tumors. Often many reports do not even give the agents used. On further analyses, the status of second-look surgery does not depend on the stage of the disease. The rate of positivity of second-look surgery for stage I disease was not statistically different than that for the combined stages II-IV, comparing this outcome using chi-square analysis (chisquare = 1.277; p = 0.258). It may be that borderline ovarian tumors are indolent in their growth, and cytotoxic agents, which generally affect rapidly progressing tumors, are ineffective.
SURVIVAL
The prolonged survival of patients with borderline ovarian tumors has been known and thus the importance of long-term follow-up is necessary. In addition, recurrences may manifest many years later. From Table 8 , it can be seen that survival for stage I disease at five years has been reported to range from 80 percent to 100 percent, and even stage III has survival ranging from 64 percent to 96 percent. Long-term follow-ups as reported by Nikrui [14] and Minyi [30] showed that, even at 15 years, there was good survival. Aure et al. [12] , in 1971, in a review of 161 patients with at least five years' follow-up, noted a steady decline in the survival of these patients, with a predicted 20-year mortality of at least 15-25 percent due to borderline ovarian tumors. Minyi et al. [30] in 1980 reported on 58 patients with borderline ovarian malignancy, with 63.8 percent of the patients treated post-operatively with adjuvant radiation or chemotherapy; of these, 51 patients had long-term follow-up; there were 18 recurrences in 14 cases documented. Only four recurrences happened within two years of the initial surgery, and 14 occurred more than five years later. The longest interval before recurrence was 27 years after the initial surgery. This report [21] 82 60
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Minyia [30] 'Estimated survival from the graphs in the paper underscores the fact that recurrences can occur late and, in fact, 77.7 percent of the recurrences in this series took place more than five years after the initial surgery. In addition, there is a report of prolonged quiescent and later spontaneous regression of borderline tumors in a 26-year-old woman who underwent a bilateral oophorectomy two and a half years after initial diagnosis; then, still untreated, had metastases resected over seven years later and was doing well more than 20 years later [43] . In Chambers et al. [17] , analysis showed no difference in the survival rates between patients who received adjuvant therapy compared to those treated with surgery alone. This result held true not only for all stages, but also for stage I alone. Table 9 contains this information on survival and status of adjuvant therapy, In an unpublished update of 140 patients with borderline ovarian tumors treated at Yale University, the overall five-year survival was 90 percent, and comparing treated patients (48 patients) and observed patients (92 patients), there was no difference in outcome. In some series, serous tumors had a better prognosis, even though these tumors usually occurred at a higher stage. CONCLUSION From this review of the literature, it is clear that the question of whether or not adjuvant treatment is necessary for borderline ovarian tumors has not been completely settled. This conclusion results from the lack of prospective randomized studies for various treatment regimens for borderline ovarian tumors. The decision to treat some patients and not other patients with the same stage of disease may have been influenced by inadequate staging in some patients or even residual disease in some; these details are not stated in the various reports. In stage I, it appears clear that surgical removal of the tumor is all that is necessary, provided that careful staging is done in order to document the full extent of the disease. Once the woman has completed her family, most authors favor removal of the other ovary, as it is at risk for subsequent development of recurrence of a borderline ovarian tumor or even carcinoma, as reported in a few cases [17, 24, 30] . There is a debate on whether or not in a young patient, presenting with unilateral disease, a biopsy of the other ovary should be done, because of the increased risk of infertility. This reviewer feels that the disease should be accurately staged and that the other ovary should be biopsied. In the more advanced stages of disease, i.e., stages II-IV, the question of need for adjuvant treatment certainly cannot be answered from the existing literature. It is clear, however, that survival cannot be shown to have been improved with any treatment. It is also important to note that patients have died from complications of therapy. In a disease which has a relatively low mortality rate, this factor must be taken into consideration. Clearly, a prospective randomized study with long follow-up is needed if the question of need for adjuvant therapy is to be critically answered. From the current literature available, this author favors surgical staging, aggressive surgical debulking of the tumor, and careful observation of the patient. If there is recurrent disease, surgery should be undertaken with the aim of removing the tumor. The Gynecologic Oncology Group (GOG) has initiated a protocol in borderline ovarian tumors to study the natural history and to assess the role of melphalan, with secondary treatment with cis-platinum, in patients who have progressive disease. In the most recent update (1989), the date from this protocol were too early to analyze. Clearly, because of the rarity of the tumor, it will be necessary to have a multi-center study in order to answer the question of the appropriate treatment, if any, for a borderline malignant ovarian tumor.
